This article reports a coupled computational experimental approach to design small molecules aimed at targeting genetic cardiomyopathies. We begin with a fully atomistic model of the cardiac thin filament. To this we dock molecules using accepted computational drug binding methodologies. The candidates are screened for their ability to repair alterations in biophysical properties caused by mutation. Hypertrophic and dilated cardiomyopathies caused by mutation are initially biophysical in nature, and the approach we take is to correct the biophysical insult prior to irreversible cardiac damage. Candidate molecules are then tested experimentally for both binding and biophysical properties. This is a proof of concept study - eventually candidate molecules will be tested in transgenic animal models of genetic (sarcomeric) cardiomyopathies.
|Original language||English (US)|
|Number of pages||10|
|State||Published - Apr 9 2019|
ASJC Scopus subject areas
- Chemical Engineering(all)